Kera Capital Partners Inc. Invests $3.79 Million in Medline $MDLN

Kera Capital Partners Inc. bought a new stake in shares of Medline (NASDAQ:MDLN) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 85,642 shares of the company’s stock, valued at approximately $3,785,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Perigon Wealth Management LLC purchased a new position in Medline during the fourth quarter worth $211,000. SteelPeak Wealth LLC purchased a new stake in shares of Medline in the fourth quarter valued at $441,000. Sound Income Strategies LLC purchased a new stake in shares of Medline in the fourth quarter valued at $25,000. Massachusetts Financial Services Co. MA bought a new stake in shares of Medline in the 4th quarter worth about $429,544,000. Finally, Baillie Gifford & Co. purchased a new position in shares of Medline during the 4th quarter worth about $437,236,000.

Insiders Place Their Bets

In other news, insider Douglas P. Golwas sold 100,000 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $36.77, for a total transaction of $3,677,000.00. Following the transaction, the insider owned 23,899 shares of the company’s stock, valued at approximately $878,766.23. This represents a 80.71% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jessi L. Corcoran purchased 5,000 shares of the business’s stock in a transaction dated Friday, June 5th. The shares were purchased at an average price of $34.15 per share, for a total transaction of $170,750.00. Following the purchase, the insider owned 5,000 shares of the company’s stock, valued at approximately $170,750. This trade represents a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.81% of the company’s stock.

Analyst Upgrades and Downgrades

MDLN has been the topic of a number of recent analyst reports. Morgan Stanley increased their price objective on shares of Medline from $48.00 to $52.00 and gave the stock an “overweight” rating in a research report on Monday, March 2nd. Citigroup dropped their target price on Medline from $60.00 to $55.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. BMO Capital Markets upped their target price on Medline from $45.00 to $54.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. JPMorgan Chase & Co. increased their price target on Medline from $50.00 to $53.00 and gave the stock an “overweight” rating in a report on Tuesday, March 10th. Finally, Royal Bank Of Canada raised their price target on Medline from $47.00 to $53.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Medline has an average rating of “Moderate Buy” and an average target price of $50.54.

Medline Price Performance

Medline stock opened at $35.94 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.51 and a current ratio of 4.41. The stock has a market cap of $47.21 billion and a PE ratio of 112.31. The firm has a 50-day moving average of $40.19. Medline has a 1 year low of $32.81 and a 1 year high of $50.88.

Medline (NASDAQ:MDLN) last issued its earnings results on Wednesday, May 6th. The company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of $0.29 by $0.04. The company had revenue of $7.35 billion for the quarter. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. Research analysts expect that Medline will post 1.49 earnings per share for the current year.

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply?chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.